Therapeutic Antibodies

#Drug discovery #High Throughput #Monoclonal antibodies #Webinar

Webinar: Applications in early monoclonal antibody discovery

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to… Read More

#News

Biologics
#Biologics #Characterisation #Formulation

App note – Light scattering measurements for biologics

The ability to monitor biologic candidates’ propensity towards self-association is critical for predicting whether a therapeutic is likely to aggregate or become difficult to administer due to viscosity. In this app note, read how Merck KGaA uses light scattering measurements to predict how formulations will behave at clinically relevant… Read More

#News

#Antibodies #Flow Cytometry #Screening

Faster, better, and more of it: What’s next for flow cytometry-based screening?

This paid-for advertorial by Bio-Rad appeared in the DDW ebook - Innovating in the lab: an essential guide to drug discovery technology. In the following article Richard J Cuthbert, PhD, Global Commercialisation Product Manager, Flow and Antibodies, Bio-Rad Laboratories examines the rise of flow cytometry as a screening tool. In recent years, the use… Read More

#Exclusive Content #Trends & Analysis

#Antibodies #Drug discovery #Drug screening

Carterra joins TetraScience Network to boost antibody services  

Life sciences company Carterra has joined data cloud company TetraScience’s network of partners to help generate insights into the potential of antibodies as drug candidates.  The Tetra Partner Network (TPN) is an ecosystem of partners which connects R&D data for pharmaceutical and biopharmaceutical customers.   Carterra… Read More

#News

#Monoclonal antibodies #Regulatory

Follow a monoclonal antibody through IND and BLA filings

In this infographic by NanoTemper, follow the steps a monoclonal antibody takes on its journey when filing for both an investigational new drug (IND) and biologics license application (BLA). In the infographic, learn about: • The typical timeline and steps for the… Read More

#News

Monoclonal antibody
#Biologics #Biopharma #Drug development

New ebook: The researcher’s guide to Dynamic Light Scattering

This e-book by NanoTemper looks at the workflows researchers are using in the biologics space and the benefits dynamic light scattering (DLS) offers. You will find out: What biologics are and why they’re important How DLS gives you information about your samples and what that data means Tips and… Read More

#News

#Antibodies #Target identification #The University of Manchester

University of Manchester expands antibody characterisation research   

The University of Manchester has added an instrument by Carterra to its Biomolecular Analysis Core Facility (BACF) within the Faculty of Biology, Medicine and Health (FBMH). The University has added Carterra’s LSA instrument to help assist with the development and characterisation of antibodies.   Created in 2005, the… Read More

#News

#Antibodies #Bi- and trispecifics #Fc-Fusion proteins #Humanisation

Understand the critical design parameters for engineering antibody formats

This whitepaper includes an introduction to antibodies and the process of antibody engineering based on Absolute Antibody’s years of experience developing recombinant versions of antibodies for a range of clients. This whitepaper will be valuable to: Therapeutic antibody developers Researchers designing antibodies for diagnostics Researchers looking to refine assays,… Read More

#News

Laboratory research
#Antibodies #Antibody Fragments #Bispecific Antibodies #Fc-Fusion proteins

App note: recombinant antibody formats, expressions & applications

Advancements in antibody engineering technologies have greatly enhanced the generation of recombinant antibodies in various formats as therapeutic agents. There are already more than 100 antibody-based drugs approved by the FDA, and numerous antibodies are currently in their late-stage clinical studies. Compared to monoclonal antibodies produced using traditional hybridoma techniques,… Read More

#News

#AstraZeneca #Clinical trials #Monoclonal antibodies

First patients dosed in trial for AstraZeneca’s Lupus treatment  

The first patients have been dosed in a Phase III clinical trial testing AstraZeneca’s treatment for lupus nephritis (LN).   The IRIS Phase III trial will be conducted in multiple countries across two years and is expected to enrol up to 360 participants aged between 18 and 70. Read More

#News

#Antibodies #Antibody reagents #Assays

Learn how to generate and validate critical antibody reagents

Antibodies are critical reagents applied in multiple biological areas, such as scientific research, therapeutics, and diagnosis. High-quality and reliable antibody reagents are the foundation of good assay performance. To learn more generating and validating critical antibody reagents join this free event hosted by DDW and supported by Sino Biological. It… Read More

#News

#Antibodies #Antibody reagents #Assays #Therapeutics

Generating and validating critical antibody reagents: event

Antibodies are critical reagents applied in multiple biological areas, such as scientific research, therapeutics, and diagnosis. High-quality and reliable antibody reagents are the foundation of good assay performance. To learn more generating and validating critical antibody reagents join this free event hosted by DDW and supported by Sino Biological. It… Read More

#News

#Automation / robotics #Biologics #Process analytical technology

Listicle: Driving production in biologics with automation 

Drug development technology has evolved rapidly in recent years, and with the industry advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. The significance of biologics is far-reaching, including treatment of rheumatologic diseases, cancer, diabetes and anaemia. The range of… Read More

#Editor's Choice #Listicles #Videos

#Automation / robotics #Biologics #Biopharma #Drug development

Driving production in biologics development with automation

Drug development technology has evolved rapidly in recent years, and with the industry, advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. Since most biologics are large molecules, they may prove challenging to develop and manufacture on the large scale. Read More

#News